Invitris
Munich, Germany· Est.
Cell‑free protein synthesis platform that accelerates protein production for therapeutics and industrial applications.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $5M
AI Company Overview
Cell‑free protein synthesis platform that accelerates protein production for therapeutics and industrial applications.
OncologyInfectious DiseasesIndustrial Biotechnology
Technology Platform
Proprietary cell‑free protein synthesis platform combining prokaryotic and mammalian extracts with Phactory™ reagents and high‑throughput microfluidic screening for rapid, scalable production of complex proteins.
Opportunities
Rapid, flexible protein production for emerging therapeutics, AMR solutions, and industrial enzymes; ability to scale from discovery to GMP manufacturing.
Risk Factors
Scaling cell‑free processes to commercial GMP volumes, regulatory acceptance of cell‑free derived therapeutics, and competition from other cell‑free platforms.
Competitive Landscape
Competes with Sutro Biopharma, Synvitrobio, and CellFree Sciences; differentiates through dual prokaryotic/mammalian systems, Phactory™ reagents, and ultra‑high‑throughput microfluidic screening.